N-[(7S)-1,2-dimethoxy-10-(methylthio)-9-oxo-3-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide is a glycoside.

Escin IA is a prodrug and its structure can be converted to desacylescin I by human intestinal bacteria and Lactobacillus brevis., desacylescin I as a biotransformation product shows potentially inhibitory effects on mouse tumor, and a potential candidate for anti tumor agents. Escin IA has anti-TNBC metastasis activity, and its action mechanisms involved inhibition of EMT process by down-regulating LOXL2 expression.